RAIN THERAPEUTICS INC.

(RAIN)
  Rapport
Vertraagde tijd Nasdaq  -  22:00 30-06-2022
5.560 USD   +12.55%
23/06RAIN THERAPEUTICS INC. : JonesTrading Institutional Services nog altijd een koopadvies
MM
02/06RAIN THERAPEUTICS INC. : Roth Capital Partners herhaalt koopadvies
MM
31/05RAIN THERAPEUTICS INC. : Piper Sandler herhaalt koopadvies
MM
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Nieuws in andere talen op RAIN THERAPEUTICS INC.
24/06RAIN THERAPEUTICS INC.(NASDAQGS : RAIN) dropped from Russell Microcap Growth Index
24/06RAIN THERAPEUTICS INC.(NASDAQGS : RAIN) dropped from Russell 2000 Value Index
24/06RAIN THERAPEUTICS INC.(NASDAQGS : RAIN) dropped from Russell 2500 Growth Index
24/06RAIN THERAPEUTICS INC.(NASDAQGS : RAIN) dropped from Russell 2000 Growth Index
24/06RAIN THERAPEUTICS INC.(NASDAQGS : RAIN) dropped from Russell 2500 Value Index
24/06RAIN THERAPEUTICS INC.(NASDAQGS : RAIN) dropped from Russell 2000 Dynamic Index
24/06RAIN THERAPEUTICS INC.(NASDAQGS : RAIN) dropped from Russell 2000 Index
24/06RAIN THERAPEUTICS INC.(NASDAQGS : RAIN) dropped from Russell 2500 Index
24/06RAIN THERAPEUTICS INC.(NASDAQGS : RAIN) dropped from Russell Small Cap Comp Value Index
24/06RAIN THERAPEUTICS INC.(NASDAQGS : RAIN) dropped from Russell 3000E Value Index
24/06RAIN THERAPEUTICS INC.(NASDAQGS : RAIN) dropped from Russell Small Cap Comp Growth Index
24/06RAIN THERAPEUTICS INC.(NASDAQGS : RAIN) dropped from Russell 3000 Growth Index
24/06RAIN THERAPEUTICS INC.(NASDAQGS : RAIN) dropped from Russell 3000E Index
24/06RAIN THERAPEUTICS INC.(NASDAQGS : RAIN) dropped from Russell 3000E Growth Index
24/06RAIN THERAPEUTICS INC.(NASDAQGS : RAIN) dropped from Russell 3000 Index
24/06RAIN THERAPEUTICS INC.(NASDAQGS : RAIN) dropped from Russell Small Cap Completeness Index
24/06RAIN THERAPEUTICS INC.(NASDAQGS : RAIN) dropped from Russell 3000 Value Index
20/06RAIN THERAPEUTICS INC.(NASDAQGS : RAIN) dropped from S&P Global BMI Index
03/06RAIN THERAPEUTICS INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
31/05Rain Therapeutics Files $250 Million Mixed Shelf
18/05Rain Therapeutics to Present on Milademetan at the 2022 American Society of Clinical On..
04/05TRANSCRIPT : Rain Therapeutics Inc., Q1 2022 Earnings Call, May 04, 2022
04/05RAIN THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and..
04/05Rain Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2..
04/05Rain Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Pr..
20/04Rain Therapeutics to Report First Quarter 2022 Financial Results and Highlights of Rece..
01/04Rain Therapeutics Announces a Poster Presentation and Trials In Progress at the America..
03/03Rain Therapeutic' Q4 Loss Narrows
03/03RAIN THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and..
03/03TRANSCRIPT : Rain Therapeutics Inc., Q4 2021 Earnings Call, Mar 03, 2022
03/03Rain Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 20..
03/03RAIN THERAPEUTICS : Reports Fourth Quarter and Full Year 2021 Financial Results and Highli..
03/03RAIN THERAPEUTICS INC. : Results of Operations and Financial Condition (form 8-K)
03/03Earnings Flash (RAIN) RAIN THERAPEUTICS Posts Q4 Loss $-0.68
03/03Rain Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Highl..
03/03Rain Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 3..
24/02Rain Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Hig..
08/02Rain Therapeutics Inc. Announces the Appointments of Several Industry Veterans to the L..
08/02Rain Therapeutics Continues to Strengthen its Leadership Team with Key Appointments
31/01Rain Therapeutics to Present at SVB Leerink Global Healthcare Conference
25/01Rain Therapeutics to Present at Upcoming Virtual Investor Conferences
13/01TRANSCRIPT : Rain Therapeutics Inc. Presents at JPMorgan 40th Annual Healthcare Conference..
05/01BOURSE ZURICH : le SMI clôture à l'équilibre
05/01Rain Therapeutics Working With Roche on Trials to Evaluate Combination Therapy in Certa..
05/01Roche met l'atézolizumab à disposition de Rain à des fins de recherche
05/01Roche schliesst Lieferabkommen mit Rain Therapeutics für Tecentriq
05/01Rain Therapeutics and Roche to Collaborate on Clinical Trial of Milademetan Combination..
05/01Rain Therapeutics and Roche to Collaborate on Clinical Trial of Milademetan Combination..
2021Rain Therapeutics to Present at Upcoming Investor Conferences
2021RAIN THERAPEUTICS INC.(NASDAQGS : RAIN) added to NASDAQ Biotechnology Index
2021Rain Therapeutics, Inc. Added to the NASDAQ Biotechnology Index
2021Rain Therapeutics to Present at Upcoming Investor Conferences
2021Rain Therapeutics Commences Dosing in Phase 2 Basket Trial of Solid Tumor Drug
2021Rain Therapeutics Doses First Patient in Phase 2 Basket Trial of Milademetan for MDM2-A..
2021Rain Therapeutics Inc. Doses First Patient in Phase 2 Basket Trial of Milademetan for M..
2021RAIN THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and..
2021Rain Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months E..
2021Rain Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Pr..
2021RAIN THERAPEUTICS INC. : Results of Operations and Financial Condition (form 8-K)
2021Rain Therapeutics Inc. Updates on Its Anticipated Near-Term Milestones
2021Earnings Flash (RAIN) RAIN THERAPEUTICS Reports Q3 Loss $-0.70
2021Rain Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Pr..
2021Rain Therapeutics to Kick Off Phase 2 Trial of Milademetan to Treat Merkel Cell Carcino..
2021Research and Development (R&D) Day Presentation - November 2021
2021Rain Therapeutics Plans Phase 2 Merkel Cell Carcinoma Clinical Trial (MANTRA-3) of Mila..
2021Rain Therapeutics Inc. Announces its Plan to Commence Phase 2 Clinical Trial, Named MAN..
2021Rain Therapeutics to Report Third Quarter 2021 Financial Results and Highlights of Rece..
2021Rain Therapeutics Hosting Research and Development (R&D) Day
2021RAIN THERAPEUTICS : Hosting Research and Development (R&D) Day
2021Certain Common Stock of Rain Therapeutics Inc. are subject to a Lock-Up Agreement Endin..
2021Certain Stock Options of Rain Therapeutics Inc. are subject to a Lock-Up Agreement Endi..
2021RAIN THERAPEUTICS : Corporate Presentation - October 2021
2021RAIN THERAPEUTICS : Presents Data on Milademetan (RAIN-32) at the 2021 AACR-NCI-EORTC Virt..
2021Rain Therapeutics Presents Data on Milademetan (RAIN-32) at the 2021 AACR-NCI-EORTC Vir..
2021RAIN THERAPEUTICS : to Present on Milademetan at the 2021 AACR-NCI-EORTC Virtual Internati..
1  2Volgende
Volgende evenement op RAIN THERAPEUTICS INC.